Guselkumab Dosage

Medically reviewed by Drugs.com. Last updated on Mar 12, 2024.

Usual Adult Dose for Psoriatic Arthritis

100 mg subcutaneously at Week 0, Week 4, and every 8 weeks thereafter

Comments:

• This drug may be administered alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate)

Uses:

• For the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

For the treatment of adults with active psoriatic arthritis

Usual Adult Dose for Plaque Psoriasis

100 mg subcutaneously at Week 0, Week 4, and every 8 weeks thereafter

Comments:

• This drug may be administered alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate)

Uses:

• For the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

For the treatment of adults with active psoriatic arthritis

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

• Hypersensitivity to the active component or any of the ingredients

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• Evaluate patients for TB prior to initiating therapy.
• Patients may self-inject after proper training in subcutaneous injection technique.
• Do not inject into areas where the skin is tender, bruised, red, hard, thick, scaly, or affected by psoriasis.

Storage requirements:

• Store in a refrigerator at 2C to 8C (36F to 46F).
• Store in original carton until time of use.
• Protect from light until use.
• Do not freeze.
• Do not shake.

Reconstitution/preparation techniques:

• Before injection, remove the prefilled syringe from the refrigerator and allow it to reach room temperature (30 minutes) without removing the needle cap.
• Inspect the liquid visually for particulate matter and discoloration prior to administration; the solution should be clear and colorless to light yellow and may contain small translucent particles. Do not use if the liquid contains large particles, is discolored, or cloudy.
• This product does not contain preservatives; therefore, discard any unused product remaining in the prefilled syringe.

Frequently asked questions

• Is Tremfya a biological?
• What are the new drugs for plaque psoriasis?
• How does Tremfya work to treat plaque and psoriatic arthritis?

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer